Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity.
Plasminogen, fibrinogen, antithrombin III, euglobulin lysis time, tissue plasminogen activator (t-PA) and fast-acting t-PA inhibitor were measured in 21 patients receiving either stanozolol (10 mg orally given for 14 days preoperatively) or subcutaneous heparin, during a continuing comparative trial in the prevention of postoperative deep vein thrombosis. Stanozolol treatment resulted in significant (p less than 0.01) increases between the 14th and 1st preoperative days in the plasma concentrations of plasminogen (3.4 to 4.9 Cu/ml) and antithrombin III (107% to 132%); t-PA levels did not increase significantly (6.0 to 16.0 mU/ml; p greater than 0.1). There were significant (p less than 0.02) falls in fast-acting t-PA inhibitor (132% to 75%) and fibrinogen (2.4 to 1.8 g/l). Surgery reversed the changes in fibrinolytic activity seen preoperatively in the stanozolol-treated patients, and similar changes were seen in the heparin-treated group. In this dosage, stanozolol does not appear to prevent the fibrinolytic shutdown which occurs after elective major surgery.
D005342:Fibrinolysis / Q000187:drug effects*; D006023:Glycoproteins / Q000378:metabolism; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D015849:Plasminogen Inactivators; D011183:Postoperative Complications / Q000517:prevention & control*; D013197:Stanozolol / Q000627:therapeutic use*; D013924:Thrombophlebitis / Q000517:prevention & control*; D013997:Time Factors
D006023:Glycoproteins; D015849:Plasminogen Inactivators; D013197:Stanozolol; D006493:Heparin